Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing people familiar with the matter.
The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don't fall apart, the people said.
The deal is supposedly Merck's biggest and represents a bet on respiratory and blood diseases treatments.
A Bloomberg report on Friday said Acceleron was in talks to be acquired for $11 billion.
Bloomberg had reported that several drugmakers, including Bristol-Myers Squibb Co (NYSE: BMY), which owns 11.5% of Acceleron's stock, were seen as potential suitors.
Related Content: Acceleron In Advanced B Buyout Talks: Bloomberg.
Reblozyl, a hematology product, is jointly co-promoted by Bristol and Acceleron. Bristol Myers has financial claims over Acceleron's products.
For sotatercept, Acceleron is required to pay Bristol-Myers a royalty in the low-20% range of global net sales if the drug is approved and commercialized to treat PAH, according to Acceleron's 2020 annual report.
Price Action: XLRN stock closed 6.69% higher at $178.87 on Monday, while MRK stock is down 0.15% at $73.25 during the premarket session on the last check Tuesday.
See more from Benzinga
Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer
Merck's Keytruda Tops Placebo On Overall Survival Endpoint In Liver Cancer Patients
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.